Potential Mechanisms of Shu Gan Jie Yu Capsule in the Treatment of Mild to Moderate Depression Based on Systemic Pharmacology and Current Evidence

Overview

Journal Evid Based Complement Alternat Med

Specialty Rehabilitation Medicine

Date 2022 Sep 1

PMID 36045654

Authors

Taiping Li

Tian Qiu

Yanyan Zeng

Bing Kang

Xianglong Tang

Ning Yang

Hong Xiao

Affiliations

Soon will be listed here.

Abstract

Background: Shu Gan Jie Yu (SGJY) capsule has a good effect on relieving depressive symptoms in China. However, the mechanism of action is still unclear. Therefore, systemic pharmacology and molecular docking approaches were used to clarify its corresponding antidepressant mechanisms.

Methods: Traditional Chinese Medicine Database and Analysis Platform (TCMSP), the Encyclopedia of Traditional Chinese Medicine (ETCM), and Swiss Target Prediction servers were used to screen and predict the bioactive components of the capsule and their antidepressive targets. Mild to moderate depression (MMD) related genes were obtained from GeneCards and DisGeNET databases. A network of bioactive components-therapeutic targets of the capsule was established by STRING 11.5 and Cytoscape 3.9.0 software. Gene function and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses were performed by utilizing Database for Annotation, Visualization, and Integrated Discovery (DAVID) platform. Active components were taken to dock with the hypothetical proteins by iGEMDOCK and SwissDock, and the docking details were visually displayed by UCSF Chimera software. Then, the related research literature of the capsule was reviewed, summarized, sorted, and analyzed, including experimental evidence and clinical experience.

Results: Seven active components and 45 intersection targets were included in the study. PPI network had genuinely uncovered the potential therapeutic targets, such as and . KEGG pathway analysis showed that the mechanism of the capsule on MMD was mainly involved in the PI3K-Akt signaling pathway.

Conclusions: In this study, we have successfully predicted the biochemically active constituents, potential therapeutic targets, and comprehensively predicted the related drug-gene interaction of the capsule for treating MMD and provided a basis for subsequent experiments.

Citing Articles

Effectiveness and safety of Arecae Semen compounds for patients with depression: a systematic review and meta-analysis.

Lin T, Zang X, Chen Y, Zhao L, Zhang Y Syst Rev. 2024; 13(1):238.

PMID: 39300549 PMC: 11411766. DOI: 10.1186/s13643-024-02656-4.

References

Yu G, Wang L, Han Y, He Q . clusterProfiler: an R package for comparing biological themes among gene clusters. OMICS. 2012; 16(5):284-7. PMC: 3339379. DOI: 10.1089/omi.2011.0118. View

Fan M, Guo D, Tian Y, Liu Y, Zhao J . Efficacy and safety of Shugan Jieyu capsule in the treatment of essential hypertension with insomnia, anxiety or depression: A protocol for systematic review and meta-analysis. Medicine (Baltimore). 2021; 100(8):e24856. PMC: 7909162. DOI: 10.1097/MD.0000000000024856. View

Chen J, Wang M, Khan R, He K, Wang Q, Li Z . The GSK3B gene confers risk for both major depressive disorder and schizophrenia in the Han Chinese population. J Affect Disord. 2015; 185:149-55. DOI: 10.1016/j.jad.2015.06.040. View

Wang C, Zhang Z, Xu Z, Shi Y, Pu M, Zheng Z . Kinase gene haplotypes and gene-gene interactions in the Ras-Raf-MAPK signaling pathway: association with antidepressant remission. Int Clin Psychopharmacol. 2013; 28(5):245-54. DOI: 10.1097/YIC.0b013e328362c89f. View

Wei Y, Qi K, Yu Y, Lu W, Xu W, Yang C . Analysis of Differentially Expressed Genes in the Dentate Gyrus and Anterior Cingulate Cortex in a Mouse Model of Depression. Biomed Res Int. 2021; 2021:5013565. PMC: 7892236. DOI: 10.1155/2021/5013565. View

Sotiropoulos I, Silva J, Gomes P, Sousa N, Almeida O . Stress and the Etiopathogenesis of Alzheimer's Disease and Depression. Adv Exp Med Biol. 2020; 1184:241-257. DOI: 10.1007/978-981-32-9358-8_20. View

Crupi R, Abusamra Y, Spina E, Calapai G . Preclinical data supporting/refuting the use of Hypericum perforatum in the treatment of depression. CNS Neurol Disord Drug Targets. 2013; 12(4):474-86. DOI: 10.2174/1871527311312040006. View

Condat A, Mouren-Simeoni M . [Selective serotonin reuptake inhibitors and depression in the child and adolescent]. Encephale. 2000; 26(3):53-60. View

Liang Y, Liang B, Chen W, Wu X, Liu-Huo W, Zhao L . Potential Mechanism of Dingji Fumai Decoction Against Atrial Fibrillation Based on Network Pharmacology, Molecular Docking, and Experimental Verification Integration Strategy. Front Cardiovasc Med. 2021; 8:712398. PMC: 8631917. DOI: 10.3389/fcvm.2021.712398. View

10.

Yao G, Li J, Wang J, Liu S, Li X, Cao X . Improved Resting-State Functional Dynamics in Post-stroke Depressive Patients After Shugan Jieyu Capsule Treatment. Front Neurosci. 2020; 14:297. PMC: 7177051. DOI: 10.3389/fnins.2020.00297. View

11.

DI Pierro F, Risso P, Settembre R . Role in depression of a multi-fractionated versus a conventional Hypericum perforatum extract. Panminerva Med. 2018; 60(4):156-160. DOI: 10.23736/S0031-0808.18.03518-8. View

12.

Felice F, Di Stefano R, Pini S, Mazzotta G, Bovenzi F, Bertoli D . Influence of depression and anxiety on circulating endothelial progenitor cells in patients with acute coronary syndromes. Hum Psychopharmacol. 2015; 30(3):183-8. DOI: 10.1002/hup.2470. View

13.

Ng Q, Venkatanarayanan N, Ho C . Clinical use of Hypericum perforatum (St John's wort) in depression: A meta-analysis. J Affect Disord. 2017; 210:211-221. DOI: 10.1016/j.jad.2016.12.048. View

14.

Zhang S, Lu Y, Chen W, Shi W, Zhao Q, Zhao J . Network Pharmacology and Experimental Evidence: PI3K/AKT Signaling Pathway is Involved in the Antidepressive Roles of Chaihu Shugan San. Drug Des Devel Ther. 2021; 15:3425-3441. PMC: 8353879. DOI: 10.2147/DDDT.S315060. View

15.

Solomon D, Adams J, Graves N . Economic evaluation of St. John's wort (Hypericum perforatum) for the treatment of mild to moderate depression. J Affect Disord. 2013; 148(2-3):228-34. DOI: 10.1016/j.jad.2012.11.064. View

16.

Huang C, You J, Wu M, Hsu K . Rap1-induced p38 mitogen-activated protein kinase activation facilitates AMPA receptor trafficking via the GDI.Rab5 complex. Potential role in (S)-3,5-dihydroxyphenylglycene-induced long term depression. J Biol Chem. 2004; 279(13):12286-92. DOI: 10.1074/jbc.M312868200. View

17.

Jalali A, Firouzabadi N, Zarshenas M . Pharmacogenetic-based management of depression: Role of traditional Persian medicine. Phytother Res. 2021; 35(9):5031-5052. DOI: 10.1002/ptr.7134. View

18.

Li Y, Xu D, Li Q . Shugan jieyu yin for treatment of senile depression--a clinical report of 84 cases. J Tradit Chin Med. 2006; 26(1):39-41. View

19.

Singer A, Schmidt M, Hauke W, Stade K . Duration of response after treatment of mild to moderate depression with Hypericum extract STW 3-VI, citalopram and placebo: a reanalysis of data from a controlled clinical trial. Phytomedicine. 2011; 18(8-9):739-42. DOI: 10.1016/j.phymed.2011.02.016. View

20.

Zhao Y, Wang Q, Jia M, Fu S, Pan J, Chu C . (+)-Sesamin attenuates chronic unpredictable mild stress-induced depressive-like behaviors and memory deficits via suppression of neuroinflammation. J Nutr Biochem. 2018; 64:61-71. DOI: 10.1016/j.jnutbio.2018.10.006. View